This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heiss, W.-D. Articles by Graf, R. Search for Related Content PubMed PubMed Citation Articles by Heiss, W.-D. Articles by Graf, R. Pubmed/NCBI databases Medline Plus Health Information Nuclear Scans Related Collections Acute Cerebral Infarction Brain Circulation and Metabolism Thrombolysis Other Stroke Treatment - Medical

(Stroke. 1999;30:1486-1489.)
© 1999 American Heart Association, Inc.

Comments, Opinions, and Reviews

Which Targets Are Relevant for Therapy of Acute Ischemic Stroke?

Wolf-Dieter Heiss, MD; Alexander Thiel, MD; Martin Grond, MD Rudolf Graf, PhD

From the Max Planck Institut für neurologische Forschung and Neurologische Universitätsklinik Köln, Köln, Germany.

Correspondence to Professor Dr W.-D. Heiss, Max Planck Institut für neurologische Forschung, Gleueler Str 50, D-50931 Köln, Germany.

Background—The efficiency of various strategies of neuroprotection is well documented in animal experiments but is thus far disappointing in ischemic stroke, for which only early reperfusion induced by thrombolysis has improved clinical outcome. This discrepancy between expectation from experimental research and clinical reality may be related to differences in the pathogenetic factors contributing to infarction.

Summary of Comment—Positron emission tomography cerebral blood flow studies within 3 hours of onset were used to identify the various compartments of the infarct outlined on MRI 2 to 3 weeks after a hemispheric stroke in 10 patients. Critical hypoperfusion below the viability threshold accounted for the largest proportion (mean, 70%) of the final infarct, whereas penumbral tissue (18%) and initially sufficiently perfused tissue (12%) were responsible for considerably smaller portions of the final infarct.

Conclusions—These results indicate that early critical flow disturbance leading to rapid cell damage is the predominant cause of infarction, while secondary and delayed pathobiochemical processes in borderline or initially sufficiently perfused regions contribute only little to the final infarct. Therefore, emerging therapeutic strategies should be targeted to the initially critically perfused tissue subcompartments. Clinical drug trials might benefit from stratification of patients for target tissue compartments applying functional imaging.

Key Words: cerebral blood flow • cerebral infarction • neuroprotection • penumbra • reperfusion • treatment

This article has been cited by other articles:

				M. K. Reddy and V. Labhasetwar Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury FASEB J, May 1, 2009; 23(5): 1384 - 1395. [Abstract] [Full Text] [PDF]

				H. Ishibashi, L. C. Pettigrew, Y. Funakoshi, and M. Hiramatsu Pharmacokinetics of Arundic Acid, an Astrocyte Modulating Agent, in Acute Ischemic Stroke J. Clin. Pharmacol., April 1, 2007; 47(4): 445 - 452. [Abstract] [Full Text] [PDF]

				M. Fabricius, S. Fuhr, R. Bhatia, M. Boutelle, P. Hashemi, A. J Strong, and M. Lauritzen Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex Brain, March 1, 2006; 129(3): 778 - 790. [Abstract] [Full Text] [PDF]

				M. Kaste Use of Animal Models Has Not Contributed to Development of Acute Stroke Therapies: Pro Stroke, October 1, 2005; 36(10): 2323 - 2324. [Full Text] [PDF]

				J. Sobesky, O. Z. Weber, F.-G. Lehnhardt, V. Hesselmann, M. Neveling, A. Jacobs, and W.-D. Heiss Does the Mismatch Match the Penumbra?: Magnetic Resonance Imaging and Positron Emission Tomography in Early Ischemic Stroke Stroke, May 1, 2005; 36(5): 980 - 985. [Abstract] [Full Text] [PDF]

				J. Sobesky, O. Z. Weber, F.-G. Lehnhardt, V. Hesselmann, A. Thiel, C. Dohmen, A. Jacobs, M. Neveling, and W.-D. Heiss Which Time-to-Peak Threshold Best Identifies Penumbral Flow?: A Comparison of Perfusion-Weighted Magnetic Resonance Imaging and Positron Emission Tomography in Acute Ischemic Stroke Stroke, December 1, 2004; 35(12): 2843 - 2847. [Abstract] [Full Text] [PDF]

				M.-C. Lin, Y.-L. Huang, H.-W. Liu, D.-Y. Yang, J.-B. Lee, and F.-C. Cheng Microdialysis Analyzer and Flame Atomic Absorption Spectrometry in the Determination of Blood Glucose, Lactate and Magnesium in Gerbils Subjected to Cerebral Ischemia/Reperfusion J. Am. Coll. Nutr., October 1, 2004; 23(5): 556S - 560S. [Abstract] [Full Text] [PDF]

				D. W. Krieger and M. A. Yenari Therapeutic Hypothermia for Acute Ischemic Stroke: What Do Laboratory Studies Teach Us? Stroke, June 1, 2004; 35(6): 1482 - 1489. [Abstract] [Full Text] [PDF]

				M. R. Macleod, T. O'Collins, D. W. Howells, and G. A. Donnan Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias Stroke, May 1, 2004; 35(5): 1203 - 1208. [Abstract] [Full Text] [PDF]

				J. M. Provenzale, R. Jahan, T. P. Naidich, and A. J. Fox Assessment of the Patient with Hyperacute Stroke: Imaging and Therapy Radiology, November 1, 2003; 229(2): 347 - 359. [Abstract] [Full Text] [PDF]

				R. Markus, D.C. Reutens, S. Kazui, S. Read, P. Wright, B.R. Chambers, J.I. Sachinidis, H.J. Tochon-Danguy, and G.A. Donnan Topography and Temporal Evolution of Hypoxic Viable Tissue Identified by 18F-Fluoromisonidazole Positron Emission Tomography in Humans After Ischemic Stroke Stroke, November 1, 2003; 34(11): 2646 - 2652. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]

				K. W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design Stroke, June 1, 2002; 33(6): 1545 - 1550. [Abstract] [Full Text] [PDF]

				H. C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, M. Kaste, P. J. Koudstaal, and T. Wessel Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo Stroke, November 1, 2000; 31(11): 2543 - 2551. [Abstract] [Full Text] [PDF]

				T. Brott and J. Bogousslavsky Treatment of Acute Ischemic Stroke N. Engl. J. Med., September 7, 2000; 343(10): 710 - 722. [Full Text] [PDF]

				M. Sakoh, L. Rohl, C. Gyldensted, A. Gjedde, L. Ostergaard, and R. A. Knight Cerebral Blood Flow and Blood Volume Measured by Magnetic Resonance Imaging Bolus Tracking After Acute Stroke in Pigs : Comparison With [15O]H2O Positron Emission Tomography Editorial Comment: Comparison With [15O]H2O Positron Emission Tomography Stroke, August 1, 2000; 31(8): 1958 - 1964. [Abstract] [Full Text] [PDF]

				M. Fisher, J.-C. Baron, W.-D. Heiss, and G. Pawlik Which Targets Are Relevant for Therapy of Acute Ischemic Stroke? • Response Stroke, April 1, 2000; 31 (4): 983 - 991. [Full Text]

				S. M. Davis, K. R. Lees, G. W. Albers, H. C. Diener, S. Markabi, G. Karlsson, and J. Norris Selfotel in Acute Ischemic Stroke : Possible Neurotoxic Effects of an NMDA Antagonist Stroke, February 1, 2000; 31(2): 347 - 354. [Abstract] [Full Text] [PDF]

				M. Grond, R. von Kummer, J. Sobesky, S. Schmulling, J. Rudolf, K. Terstegge, and W.-D. Heiss Early X-Ray Hypoattenuation of Brain Parenchyma Indicates Extended Critical Hypoperfusion in Acute Stroke Stroke, January 1, 2000; 31(1): 133 - 139. [Abstract] [Full Text] [PDF]